Project Description

PreView Medical uses AI-powered spectroscopy to classify tissue in real time as benign or malignant

The company’s initial application is prostate cancer, the second most common cancer in men. The gold standard for prostate cancer detection, ultrasound-guided biopsy, misses 40% of all cancers. PreView’s ClariCore system provides urologists with real-time tissue characterization during the prostate biopsy procedure, potentially allowing them to detect more cancers. PreView’s technology also can be used to map a tumor, enabling more targeted focal therapies that could provide an alternative to radical prostatectomies for many men, thus reducing the significant complications of impotence and incontinence.